| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 8, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal®...
-
Aug 18, 2008- Full year revenue increased $375 million, or 26 percent, to a record $1.8 billion, including $500 million for the fourth quarter
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 28, 2008. Perrigo's Chairman and CEO Joseph C. Papa commented, "For the third...
-
Aug 13, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on September 16, 2008 to shareholders of record on...
-
Aug 11, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it began shipping Famotidine Complete chewable tablets (famotidine 10 mg; calcium carbonate 800mg; magnesium hydroxide 165 mg) to...
-
Aug 5, 2008In the release, Perrigo Company to Present at the Bank of America Specialty Pharmaceuticals Conference, issued earlier today by Perrigo Company (Nasdaq: PRGO; TASE), over PR Newswire, we are advised by the Company that the first sentence of the first para
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's Chief Financial Officer, will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...